These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Mateu de Antonio J; Grau S; Morales-Molina JA; Marín-Casino M Clin Infect Dis; 2006 May; 42(10):1500; author reply 1501. PubMed ID: 16619168 [No Abstract] [Full Text] [Related]
5. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. Tsuji Y; Hiraki Y; Matsumoto K; Mizoguchi A; Kobayashi T; Sadoh S; Morita K; Kamimura H; Karube Y J Infect Chemother; 2011 Feb; 17(1):70-5. PubMed ID: 20582446 [TBL] [Abstract][Full Text] [Related]
6. Linezolid and reversible myelosuppression. Arellano FM JAMA; 2001 Oct 24-31; 286(16):1973-4; discussion 1974. PubMed ID: 11667930 [No Abstract] [Full Text] [Related]
7. Linezolid-Induced anemia and thrombocytopenia. Waldrep TW; Skiest DJ Pharmacotherapy; 2002 Jan; 22(1):109-12. PubMed ID: 11794421 [TBL] [Abstract][Full Text] [Related]
8. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Minson Q; Gentry CA Pharmacotherapy; 2010 Sep; 30(9):895-903. PubMed ID: 20795845 [TBL] [Abstract][Full Text] [Related]
9. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Hiraki Y; Tsuji Y; Matsumoto K; Morita K; Kamimura H; Karube Y Am J Med Sci; 2011 Dec; 342(6):456-60. PubMed ID: 21681075 [TBL] [Abstract][Full Text] [Related]
10. Linezolid and reversible myelosuppression. Green SL; Maddox JC; Huttenbach ED JAMA; 2001 Mar; 285(10):1291. PubMed ID: 11255382 [No Abstract] [Full Text] [Related]
11. Linezolid and reversible myelosuppression. Lawyer MC; Lawyer EZ JAMA; 2001 Oct 24-31; 286(16):1974. PubMed ID: 11667931 [No Abstract] [Full Text] [Related]
15. Safety and tolerability of linezolid. French G J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii45-53. PubMed ID: 12730142 [TBL] [Abstract][Full Text] [Related]
16. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Rao N; Ziran BH; Wagener MM; Santa ER; Yu VL Clin Infect Dis; 2004 Apr; 38(8):1058-64. PubMed ID: 15095207 [TBL] [Abstract][Full Text] [Related]
17. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Plachouras D; Giannitsioti E; Athanassia S; Kontopidou F; Papadopoulos A; Kanellakopoulou K; Giamarellou H Clin Infect Dis; 2006 Nov; 43(9):e89-91. PubMed ID: 17029128 [TBL] [Abstract][Full Text] [Related]
19. Hematologic effects of linezolid versus vancomycin. Young LS Clin Infect Dis; 2004 Apr; 38(8):1065-6. PubMed ID: 15095208 [No Abstract] [Full Text] [Related]
20. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Soriano A; Ortega M; García S; Peñarroja G; Bové A; Marcos M; Martínez JC; Martínez JA; Mensa J Antimicrob Agents Chemother; 2007 Jul; 51(7):2559-63. PubMed ID: 17470658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]